Current Agreements

Dealdoc

Distribution and marketing agreement for Bystolic (nebivolol) and Savella (milnacipran HCl) (terminated)

Forest Laboratories
Janssen Pharmaceutica NV
Janssen Pharmaceuticals

Nov 11 2010

Distribution and marketing agreement for Bystolic (nebivolol) and Savella (milnacipran HCl) (terminated)

Companies:	Forest Laboratories Janssen Pharmaceutica NV Janssen Pharmaceuticals
Announcement date:	Nov 11 2010
Deal value, US$m:	n/d

- Details
- Financials
- Termsheet
- Press Release
- Filing Data
- Contract

Details

Announcement date:	Nov 11 2010
Termination date:	Apr 02 2012
Industry sectors:	Bigpharma Pharmaceutical
Therapy areas:	Cardiovascular » Hypertension Central Nervous System » Pain Musculoskeletal
Technology types:	Small molecules
Deal components:	Co-promotion Distribution Marketing Sub-license Termination
Stages of development:	Marketed
Geographic focus:	North America » Canada

Financials

Deal value, US$m:	n/d
Upfront, US$m:	n/d : upfront payment
Milestones, US$m:	n/d : milestone payment
Royalty rates, %:	n/d : sales related royalty payments

Termsheet

2 April 2012

Forest and Janssen terminated the licenses in Canada for both Bystolic and Savella (milnacipran) with Janssen Pharmaceutica NV and Janssen Pharmaceutical, respectively.

Forest has now established its Canadian subsidiary, which will take over the registration and commercialization of both products.

---

11 November 2010

Forest has entered into a definitive collaboration and distribution agreement for Bystolic® (nebivolol) and Savella® (milnacipran HCl) in Canada with Janssen Pharmaceutica, NV and Janssen Pharmaceutical respectively, on behalf of Janssen Inc., which will market the products in

Canada.

Janssen Pharmaceutica NV and Janssen Pharmaceutical will pay Forest an undisclosed signing fee, milestones and sales-related royalties in exchange for exclusive sublicenses to Janssen Inc. for the commercialization of Bystolic® and Savella® in Canada

Press Release

2 April 2012

NEW YORK--(BUSINESS WIRE)-- Forest Laboratories, Inc. (NYSE: FRX - News) today announced that Forest Laboratories Holdings Limited (Forest), its wholly owned subsidiary, and Janssen Pharmaceutica NV (Janssen) entered into an agreement under which Forest acquired all U.S. patents and other U.S. and Canadian intellectual property for Bystolic® (nebivolol), which is currently approved in the United States for the treatment of hypertension, thereby eliminating all future royalties. The acquisition was completed simultaneously with the execution of the agreement on March 30.

Under the terms of this agreement, Forest made a one-time cash payment of $357 million to Janssen, and Janssen assigned to Forest all U.S. patents and other U.S. and Canadian know-how covering Bystolic®, including the nebivolol composition of matter patent in the U.S. Forest will amortize the one-time cash payment over the remaining patent life of Bystolic.

In addition, contemporaneously with the closing of the acquisition, Forest and Janssen terminated the licenses in Canada for both Bystolic and Savella® (milnacipran) with Janssen Pharmaceutica NV and Janssen Pharmaceutical, respectively. Forest has now established its Canadian subsidiary, which will take over the registration and commercialization of both products.

Forest Laboratories Enters Collaboration on Bystolic® and Savella® in Canada

11 November 2010

NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (Forest) (NYSE: FRX) today announced that Forest Laboratories Holdings Limited, its wholly owned subsidiary, has entered into a definitive collaboration and distribution agreement for Bystolic® (nebivolol) and Savella® (milnacipran HCl) in Canada with Janssen Pharmaceutica, NV and Janssen Pharmaceutical respectively, on behalf of Janssen Inc., which will market the products in Canada.

Under the terms of the agreement, Janssen Pharmaceutica NV and Janssen Pharmaceutical will pay Forest an undisclosed signing fee, milestones and sales-related royalties in exchange for exclusive sublicenses to Janssen Inc. for the commercialization of Bystolic® and Savella® in Canada.

Janssen Inc. is headquartered in Toronto and markets a broad range of medications used in psychiatry, dementia, attention deficit hyperactivity disorder, psoriasis, pain management, women’s health, infectious disease, anemia, oncology, and virology. Janssen Inc. will assume responsibility for the Canadian regulatory approval and commercialization of Bystolic® and Savella® in Canada. Forest will have the opportunity to co-promote at any time after the first anniversary of regulatory approval for either product.

Over the next few years, Forest plans to establish a wholly owned Canadian affiliate that will exercise the co-promotion rights for Bystolic® and Savella® in Canada, and that will also take responsibility for the future regulatory filings and commercialization of its pipeline products in Canada. Current late-stage products for which Forest holds Canadian rights include Teflaro™ (ceftaroline), linaclotide, F-2695 and cariprazine.

Howard Solomon, Chairman and Chief Executive Officer of Forest Laboratories said, "We are pleased to have entered into this collaboration for the commercialization of Bystolic® and Savella® in Canada. This collaboration is a significant and valuable first step towards establishing a Forest presence in Canada. We look forward to the expansion of Forest Laboratories into Canada.”

Bystolic® (nebivolol) was approved by the U.S. Food and Drug Administration for the treatment of hypertension (chronic high blood pressure). Savella® was approved by the U.S. Food and Drug Administration for the management of fibromyalgia.

About Forest Laboratories

Forest Laboratories’ (NYSE: FRX) longstanding global partnerships and track record developing and marketing pharmaceutical products in the United States have yielded its well-established central nervous system and cardiovascular franchises and innovations in anti-infective medicine. The Company’s pipeline, the most robust in its history, includes product candidates in all stages of development across a wide range of therapeutic areas. The Company is headquartered in New York, NY. To learn more, visit www.FRX.com.

Except for the historical information contained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in Forest Laboratories' Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and any subsequent SEC filings.

Filing Data

Not available.

Contract

Not available.